Plasma asymmetric dimethylarginine modifies the effect of pravastatin on myocardial blood flow in young adults

Vascular Medicine

Volumn 8, Issue 3, 2003, Pages 185-189

  Janatuinen, Tuula ^a   Laakso, Juha ^b   Laaksonen, Reijo ^b,c   Vesalainen, Risto ^a   Nuutila, Pirjo ^a   Lehtimäki, Terho ^d   Raitakari, Olli T ^a   Knuuti, Juhani ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^d TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

Asymmetric dimethylarginine; Blood flow; Positron emission tomography; Pravastatin

Indexed keywords

ADENOSINE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; OXYGEN 15; PLACEBO; PRAVASTATIN; WATER;

ADULT; ARTICLE; BLOOD FLOWMETRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FOLLOW UP; HEART MUSCLE BLOOD FLOW; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERCHOLESTEROLEMIA; HYPEREMIA; ISOTOPE LABELING; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; REST; STATISTICAL SIGNIFICANCE;

ADENOSINE; ADULT; ANTICHOLESTEREMIC AGENTS; ARGININE; BLOOD FLOW VELOCITY; CORONARY CIRCULATION; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; HUMANS; HYPEREMIA; MALE; NITRIC OXIDE SYNTHASE; PRAVASTATIN; REGIONAL BLOOD FLOW; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 1242295337     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1191/1358863x03vm490oa     Document Type: Article

References (20)

1. Böger RH, Bode-Böger SM, Szuba A et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998; 98: 1842-47.
2. Miyazaki H, Matsuoka H, Cooke JP et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999; 99: 1141-46.
3. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572-75.
4. Surdacki A, Nowicki M, Sandmann J et al. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 1999; 33: 652-58.
5. Päivä H, Laakso J, Laine H, Laaksonen R, Knuuti J, Raitakari OT. Plasma asymmetric dimethylarginine and hyperemic myocardial blood flow in young objects with borderline hypertension or familial hypercholesterolemia. J Am Coll Cardiol 2002; 40: 1241-47.
6. Usui M, Matsuoka H, Miyazaki H, Ueda S, Okuda S, Imaizumi T. Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. Life Sci 1998; 62: 2425-30.
7. Valkonen VP, Päivä H, Salonen JT et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001; 358: 2127-28.
8. Zoccali C, Bode-Böger S, Mallamaci F et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-state renal disease: a prospective study. Lancet 2001; 358: 2113-17.
9. Janatuinen T, Laaksonen R, Vesalainen R et al. Effect of lipid-lowering therapy with pravastatin on myocardial blood flow in young mildly hypercholesterolemic adults. J Cardiovasc Pharmacol 2001; 38: 561-68.
10. Kaesemeyer WH, Caldwell RB, Huang J, Caldwell RW. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol 1999; 33: 234-41.
11. Laufs, U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97: 1129-35.
12. Fleck C, Janz A, Schweitzer F, Karge E, Schwertfeger M, Stein G. Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in renal failure patients. Kidney Int Suppl 2001; 78: S14-S18.
13. Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999; 99: 3092-95.
14. Stühlinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, Cooke JP. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation 2001; 104: 2569-75.
15. Iida H, Kanno I, Takahashi A et al. Measurement of absolute myocardial blood flow with H215O and dynamic positron-emission tomography. Strategy for quantification in relation to the partial-volume effect. Circulation 1988; 78: 104-15.
16. Iida H, Takahashi A, Tamura Y, Ono Y, Lammertsma AA. Myocardial blood flow: comparison of oxygen-15-water bolus injection, slow infusion and oxygen-15-carbon dioxide slow inhalation. J Nucl Med 1995; 36: 78-85.
17. Iida H, Rhodes CG, de Silva R et al. Use of the left ventricular time-activity curve as a noninvasive input function in dynamic oxygen-15-water positron emission tomography. J Nucl Med 1992; 33: 1669-77.
18. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
19. Lehtimaki T, Lehtinen S, Solakivi T et al. Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease. Arterioscler Thromb Vasc Biol 1999; 19: 23-27.
20. Buus NH, Bottcher M, Hermansen F, Sander M, Nielsen TT, Mulvany MJ. Influence of nitric oxide synthase and adrenergic inhibition on adenosine-induced myocardial hyperemia. Circulation 2001; 104: 2305-10.